Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.

ABSTRACT: Although lower grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1-mutant patients are increasingly being treated with temozolomide, but early detection of response remains a challenge and there is a need for complementary imaging methods to assess response to therapy prior to tumor shrinkage. The goal of this study was to determine the value of magnetic resonance spectroscopy (MRS)-based metabolic changes for detection of response to temozolomide in both genetically engineered and patient-derived mutant IDH1 models. Using ¹H MRS in combination with chemometrics identified several metabolic alterations in temozolomide-treated cells, including a significant in

SUBMITTER: Subramani E 

PROVIDER: S-EPMC7669718 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature